Tecvayli Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of multiple myeloma disease progression, expansion of biologic drug development capabilities, increased availability of specialty oncology clinics, regulatory approvals for advanced immunotherapies, rising demand for relapse management solutions.

The growth in the forecast period can be attributed to expansion of next-generation immuno-oncology pipelines, increasing adoption of personalized cancer therapies, rising investments in hematologic malignancy research, growing use of real-world evidence in oncology care, expansion of access to advanced biologics in emerging markets. Major trends in the forecast period include expansion of bispecific antibody therapies, growing adoption of bcma-targeted treatments, rising use of combination therapy approaches, increasing focus on late-line multiple myeloma care, enhanced patient monitoring during immunotherapy.

The rising prevalence of multiple myeloma is expected to support the expansion of the tecvayli market in the coming years. Multiple myeloma is a cancer of plasma cells that remains difficult to treat, particularly in relapsed or refractory stages. The increase in multiple myeloma cases is driven by factors such as aging populations and improvements in diagnostic techniques, which together contribute to higher demand for effective and targeted therapies. Tecvayli addresses multiple myeloma by enhancing T-cell-mediated destruction of myeloma cells, reducing tumor burden, and improving outcomes for patients with relapsed or refractory disease. For instance, in August 2024, according to the American Cancer Society, a US-based professional organization, approximately 35,780 new cases of multiple myeloma were projected to be diagnosed in the United States in 2024, including 19,520 cases in men and 16,260 cases in women. Additionally, the disease was estimated to cause 12,540 deaths, comprising 7,020 men and 5,520 women. Therefore, the increasing prevalence of multiple myeloma is driving the growth of the tecvayli market.

The growing investment in cancer research is expected to contribute to the growth of the tecvayli market going forward. Cancer research involves scientific investigations aimed at understanding the causes, biology, diagnosis, treatment, and prevention of cancer in order to develop more effective therapies and improve patient outcomes. Increased funding for cancer research is driven by rising cancer incidence, heightened public awareness, the promise of breakthrough treatments, and the need for more personalized and effective therapeutic options. Greater research investment often leads to improved dosing regimens, fewer side effects, and more optimized treatment protocols, which enhance the attractiveness of Tecvayli for both healthcare providers and patients. For instance, in 2023, according to the American Society for Radiation Oncology (ASTRO), a US-based professional organization, the National Cancer Institute allocated approximately $7.3 billion to cancer research, representing a 5.9% increase compared with the previous year, with a substantial portion directed toward research grants and clinical trials, including an additional $407.6 million specifically dedicated to cancer research initiatives. Therefore, increased investment in cancer research is supporting the expansion of the tecvayli market.

Major companies operating in the tecvayli market are increasingly focused on developing innovative therapies, including monoclonal antibody-based treatments, to address the growing demand for more targeted, effective, and durable options for hematologic cancers. Monoclonal antibody therapies are laboratory-engineered molecules designed to bind to specific proteins on cancer cells and activate immune-mediated destruction, offering a more precise approach than conventional chemotherapy, which affects both healthy and malignant cells. For example, in February 2024, Johnson & Johnson Services Inc., a US-based pharmaceutical company, received approval from the US Food and Drug Administration for a supplemental Biologics License Application for TECVAYLI (teclistamab-cqyv), allowing a reduced dosing schedule of 1.5 mg/kg administered every two weeks in patients with relapsed or refractory multiple myeloma. TECVAYLI is a first-in-class bispecific B-cell maturation antigen-directed CD3 T-cell engager approved for the treatment of adult patients with relapsed or refractory multiple myeloma.

Major companies operating in the tecvayli market are Johnson And Johnson.

North America was the largest region in the tecvayli market in 2025. The regions covered in the tecvayli market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tecvayli market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the tecvayli market by increasing costs of imported biologic substances, specialized cell-culture materials, pharmaceutical-grade packaging, and cold-chain logistics required for bispecific antibody therapies. North America and Europe are most affected due to dependence on global biologics manufacturing networks and high-value imports. These tariffs are raising treatment costs and impacting reimbursement dynamics for advanced myeloma therapies. At the same time, they are driving investments in regional biologics manufacturing, localized fill-finish operations, and domestic supply chain resilience for complex oncology drugs.

The tecvayli market research report is one of a series of new reports that provides tecvayli market statistics, including tecvayli industry global market size, regional shares, competitors with a tecvayli market share, detailed tecvayli market segments, market trends and opportunities, and any further data you may need to thrive in the tecvayli industry. This tecvayli market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tecvayli (generic name: teclistamab) is a prescription medicine indicated for the treatment of adults with relapsed or refractory multiple myeloma, a blood cancer that affects plasma cells, who have previously undergone at least four prior therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.

The primary therapy types for Tecvayli include monotherapy and combination therapy. Monotherapy refers to the management of a disease using a single drug or treatment approach and is often selected when it is adequate to control the condition. Tecvayli is used for indications such as relapsed multiple myeloma and refractory multiple myeloma. The drug is distributed through channels including hospital pharmacies, specialty clinics, and online pharmacies, and it serves end users across adult and geriatric patient populations.

The tecvayli market consists of sales of associated diagnostics, supportive care therapies, injection devices, biosimilars, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.